Gustavo Viani, Professor at the Faculty of Medicine of Botucatu, São Paulo State University (UNESP), shared a post on LinkedIn:
“START the NEW ERA!: SAbR Delivers 5-Year Survival With Zero ≥G3 Toxicity for Lung Cancer
Special thanks to Fabio Arcidiacono and Paola Anselmo for the teamwork and partnership in this important publication.
The Gap
Frail stage III NSCLC patients unfit for concurrent chemo-RT had no radical option beyond palliative RT.
The Results
- Phase II, 50 pts (median age 73)
- VMAT-SAbR: 45/40 Gy × 5
- 5-yr OS: 46% | PFS: 26%
- No ≥G3 late toxicities
- Re-SAbR feasible for salvage
Impact
SAbR emerges as a safe and effective radical alternative for frail LA-NSCLC patients — ≥40 Gy/5 is key for durable local control.
More from Gustavo Viani on OncoDaily.